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Abstract Granulomatosis with polyangiitis and micro-
scopic polyangiitis are anti-neutrophil cytoplasmic anti-
body-associated vasculitides (AAVs) that are prone to
cycles of remission and relapse. The introduction of cyto-
toxic therapy has changed the prognosis for these diseases
from typically fatal to manageable chronic illnesses with a
relapsing course. Despite improvements in outcomes,
recurrence of disease and drug-related toxicity continue to
produce significant morbidity and mortality. Better under-
standing of the pathogenesis of AAV and the mechanism of
action of cyclophosphamide has led to investigation of
therapies that target B cells. Two randomized controlled
trials have shown that rituximab is not inferior to cyclo-
phosphamide for induction of remission in severe AAV,
with no significant difference in the incidence of overall
adverse events in rituximab- versus cyclophosphamide-
treated patients. Data from ongoing clinical trials will
determine the role of rituximab in the maintenance of
remission.
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Introduction
Granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA) are rare small-vessel vasculitides that
are characterized by the presence of circulating anti-neu-
trophil cytoplasmic autoantibodies (ANCAs) in 80–94 %
of affected patients [1, 2]. The prevalence of ANCA-
associated vasculitis (AAV) has increased in recent years,
in part due to increased recognition of these complex dis-
eases. AAVs have an annual incidence of 20 per million
population [3]. Renal involvement is present in [50 % of
patients at presentation and develops in 70–80 % during
the course of the disease. The typical histopathology is a
focal segmental and necrotizing crescentic glomerulone-
phritis (GN) with minimal immunoglobulin deposition in
vessel walls [4]. GPA and MPA account for 80 % of cases
of rapidly progressive GN [5]. Progression to end-stage
renal disease (ESRD) can be prevented by prompt diag-
nosis and timely initiation of therapy.
GPA and MPA are severe, progressive diseases that, left
untreated, can lead to death from multisystem organ
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failure. The introduction of therapy with glucocorticoids
combined with cyclophosphamide improved the prognosis
for AAV [6]. However, not all patients respond to cyclo-
phosphamide, and [50 % of responders suffer a relapse
within 3–5 years [7]. Disease recurrence and drug-related
toxicity continue to produce significant morbidity and
mortality, and remain the main challenges in patient
management [8]. In a recent analysis of four European
clinical trials involving 524 AAV patients, the greatest
impact on patients in the first year of therapy was from
adverse events (AEs) rather than active vasculitis [9]. In
this analysis, the burden of AEs was quantified using a
severity score for leukopenia, infection, and other AEs with
additional weighting for follow-up duration. The burden of
AEs was predicted by the severity of renal impairment and
advanced age.
ANCAs are implicated in the pathogenesis of GPA and
MPA [10]. Consequently, therapies targeting the cells that
produce these antibodies (short-lived plasma cells of B-cell
origin) and other functions of B cells, such as antigen
presentation and cytokine release, have been considered as
potential treatments for AAV. After promising initial data
from smaller studies, two randomized clinical trials have
shown that rituximab, an anti-CD20 monoclonal antibody
that targets B cells, is not inferior to cyclophosphamide for
induction of remission in severe GPA and MPA [11, 12].
Consequently, in April 2011 the US FDA approved ritux-
imab for the treatment of these diseases, heralding a new
era in disease management. The aim of this review is to
examine the latest evidence supporting the use of rituximab
in GPA/MPA within the context of other available treat-
ment approaches.
Current treatment options
The European Vasculitis Study Group (EUVAS) classifies
AAV according to particular subtypes in order to assign
different treatment regimens (Table 1) [13]. Therapy con-
sists of a staged treatment approach involving two treat-
ment phases: remission-induction and remission-
maintenance.
Standard of care
Combination therapy with corticosteroids and cyclophos-
phamide was established as standard therapy after the
seminal paper published by Fauci et al. [6]. Prolonged
courses of cyclophosphamide are effective for the treat-
ment of AAV, with 91 % of patients showing improvement
in disease status and 75 % achieving sustained disease
remission. However, the cost of achieving remission using
this extended cyclophosphamide dosing regimen was sub-
stantial: 46 % of patients developed a serious infection,
57 % became infertile, and 43 % developed hemorrhagic
cystitis. In addition, there was a 33-fold increased risk of
bladder carcinoma and an 11-fold increased risk of lym-
phoma. Overall, 42 % of patients developed some form of
serious morbidity directly attributable to therapy when
cyclophosphamide was used for 2 years according to the
NIH regimen. Modern treatment strategies have focused on
minimizing cyclophosphamide exposure or eliminating its
use altogether. Pulsed cyclophosphamide administration
has been considered as a less toxic alternative to daily
cyclophosphamide [14, 15]. Both pulsed cyclophospha-
mide [15 mg/kg intravenously (IV) every 2–3 weeks] and





Localized Upper and/or lower respiratory tract
disease without other systemic
involvement or constitutional symptoms





Without organ-threatening or life-
threatening disease
Methotrexate or cyclophosphamide ? steroids Low-dose
steroids ? azathioprine
or methotrexate
Generalized Renal or other life-threatening disease;
serum creatinine \500 lmol/l




Severe Renal or other vital organ failure; serum
creatinine [500 lmol/l




Refractory Progressive disease unresponsive to
cyclophosphamide and glucocorticoids





a Rituximab can be recommended for newly diagnosed, relapsing, and refractory disease
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daily cyclophosphamide (2 mg/kg/day) produce similar
remission rates, although long-term follow-up of patients
enrolled in the CYCLOPS trial indicates that the risk of
relapse continues to increase among patients treated with
pulsed cyclophosphamide [16]. Between 10 and 40 % of
patients fail to achieve sustained remission with standard
induction therapy through inefficacy, severe AEs, or
intolerance [14–16].
For remission-maintenance, the CYCAZAREM trial
showed that cyclophosphamide could be replaced with
azathioprine after remission without increasing the rate of
relapse [17]. Azathioprine and low-dose steroid tapered to
B10 mg/day are recommended to reduce exposure to
cyclophosphamide and steroids, although relapses occur in
[50 % of patients by 7 years [13, 17, 18]. The IMPROVE
trial tested the use of mycophenolate mofetil (MMF) as a
remission-maintenance agent in 156 patients with AAV
[19]. The rate of relapse with MMF 2,000 mg daily with
dose further reduced at 12 months to 1,500 mg daily and at
18 months to 1,000 mg daily was almost double that
observed with azathioprine 2 mg/kg/day [adjusted hazard
ratio for relapse associated with MMF, 1.80 (95 % confi-
dence interval 1.10–2.93); P = 0.02], indicating that MMF
at the dose used is not as effective as azathioprine for
maintaining disease remission. Methotrexate is another
alternative as a remission-maintenance agent [20].
Alternatives to standard of care
Standard of care for remission-induction may not be suf-
ficient or appropriate for all patients with GPA/MPA.
Methotrexate can be used as an alternative to cyclophos-
phamide in patients without renal involvement or with only
mild renal involvement (early systemic disease) [21].
Long-term observation, however, shows that induction
treatment with methotrexate results in less effective disease
control than cyclophosphamide-based induction therapy
[22]. MMF is an alternative to cyclophosphamide for
remission-induction in patients with mild to moderate renal
disease [23]. A randomized, non-inferiority trial (MYCYC)
compared remission-induction with MMF or cyclophos-
phamide in newly diagnosed GPA/MPA. The study did not
reach its primary endpoint of demonstrating that MMF is
non-inferior to cyclophosphamide in terms of remission-
induction when steroids were used according to protocol,
although non-inferiority was shown for remission-induc-
tion irrespective of steroid compliance [24].
For patients with severe (life-threatening) AAV,
adjunctive plasma exchange may be considered. MEPEX
was a randomized, controlled trial comparing IV methyl-
prednisolone or plasma exchange with cyclophosphamide
and oral prednisolone in severe renal vasculitis, with renal
recovery as the primary outcome measure [25]. At
3 months, a significantly greater proportion of patients who
received plasma exchange were alive and independent of
dialysis compared with those who received IV methyl-
prednisolone (69 versus 49 %, P = 0.02), thus supporting
the use of plasma exchange in the treatment of AAV with
renal failure. The use of adjunctive plasma exchange with
standard immunosuppressive therapy and glucocorticoids
in less severe renal disease is being investigated in PEXI-
VAS, a large international multicenter trial.
Rituximab
Rationale for B-cell-targeted therapy
Rituximab was first FDA approved in 1997 for the treat-
ment of non-Hodgkin lymphoma. It is also licensed in
rheumatoid arthritis (RA) for treating patients with an
inadequate response to tumor necrosis factor-a inhibitors.
Rituximab has also been studied in patients with glomer-
ular diseases, including lupus nephritis, membranous
nephropathy, and focal glomerulosclerosis [26–29]. The
rationale for using rituximab in GPA/MPA stems from the
central role played by B cells in the pathogenesis of these
diseases and evidence for the pathogenicity of circulating
ANCAs [30]. B cells are the precursors of short-lived
plasma cells, which are thought to be the primary source of
autoantibodies, including ANCAs. B cells may contribute
to other aspects of the pathogenesis of GPA and MPA,
including co-stimulation, cytokine production, and antigen
presentation [30]. The action of cyclophosphamide also
points to a role for B cells, as it may exert some of its
activity in GPA/MPA through the suppression of B-cell
function [31].
Rituximab for remission-induction in GPA/MPA
Patients with GPA/MPA have experienced remission rates
of approximately 90 % with rituximab in open-label clin-
ical trials and case series [32–34]. However, these studies
were neither randomized nor controlled, and criteria for
remission were not rigidly applied. Two recent randomized
controlled trials (RAVE and RITUXVAS) investigated the
efficacy and safety of rituximab in GPA/MPA. The US
FDA approval of rituximab was based on data from the
RAVE study [11]. RAVE enrolled 197 patients with severe
GPA/MPA, approximately 50 % of whom had newly
diagnosed disease and 50 % had severe relapsing disease at
diagnosis. Patients with severe renal impairment (serum
creatinine [4 mg/dl) and those requiring intubation for
alveolar hemorrhage were excluded. However, 66 % of
each group had renal disease at baseline, and lung
involvement was present in a little over half of each group
J Nephrol (2015) 28:17–27 19
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with pulmonary hemorrhage in approximately one quarter
of each group.
This was a double-blind, double-dummy, controlled,
randomized trial with preset primary, secondary, and ter-
tiary endpoints. Patients were randomized to receive either
rituximab (375 mg/m2 once weekly for 4 weeks) or oral
cyclophosphamide (2 mg/kg/day) for a maximum of
6 months (remission-induction period). All patients
received the same glucocorticoid regimen (1–3 pulses of
IV methylprednisolone 1,000 mg, followed by oral pred-
nisone 1 mg/kg tapered over 5 months). On achieving
remission at 3–6 months, patients in the cyclophosphamide
arm were switched to a remission-maintenance regimen of
azathioprine 2 mg/kg/day. Patients in the rituximab group
who achieved remission during the same period were
maintained on placebo rather than azathioprine after initial
rituximab except for a tapering corticosteroid dose similar
to the cyclophosphamide group, They thus received no
active treatment after 5 months, when their prednisone was
discontinued. Patients were followed for at least 18 months
to gauge long-term responses and the effect of rituximab on
immune tolerance. The primary endpoint was achievement
of complete remission, as defined by a Birmingham Vas-
culitis Activity Score for Wegener’s Granulomatosis
(BVAS/WG) [35] of zero and no prednisone by 6 months.
At 6 months, 64 % of rituximab-treated patients
achieved the primary endpoint versus 53 % in the cyclo-
phosphamide group, a result that met the criterion for non-
inferiority (P \ 0.001). In patients with relapsing disease at
baseline, 67 % (34/51) of patients in the rituximab group
and 42 % (21/50) of patients in the cyclophosphamide
group achieved complete remission (P = 0.01). A sec-
ondary endpoint was remission defined as BVAS/WG of 0
and prednisone B10 mg/day; this endpoint was achieved
by 71 % of rituximab- and 62 % of cyclophosphamide-
treated patients. Results from the long-term follow-up of
the RAVE trial showed 48 and 39 % of patients in the
rituximab arm were in sustained remission at 12 and
18 months compared to 39 and 33 % of patients in the
CYC arm, demonstrating that remission-induction with
rituximab without any maintenance therapy was non-infe-
rior to CYC followed by azathioprine [36].
Approximately half of the patients in RAVE had major
renal disease at baseline (Box 1). Although baseline mean
estimated glomerular filtration rate (e-GFR) was signifi-
cantly worse in the rituximab group (creatinine clearance
53 versus 69 ml/min; P = 0.01), the proportion of renal
patients achieving the study primary endpoint was not
significantly different between the two groups (rituximab
61 % versus cyclophosphamide 63 %; P = 0.92) [37].
There was no difference in the proportion of patients with
sustained remission at 18 months (rituximab 42 % versus
cyclophosphamide 43 %; P = 0.84). Mean e-GFR also
increased in parallel in both groups. There was no overall
difference in the incidence of renal flares between groups;
however, MPA patients treated with rituximab were more
likely to experience renal flares than those treated with
cyclophosphamide/azathioprine (4 MPA patients treated
with rituximab had a total of 5 renal flares by month 18
versus none treated with cyclophosphamide/azathioprine;
P = 0.04).
The safety data from RAVE showed no significant dif-
ferences between the treatment groups in the incidence of
AEs, serious AEs, or non-disease-related AEs [11]. There
were more infusion reactions with rituximab (but only
during the initial infusion—12 vs. 7 %) and serious
infections (sepsis and pneumonia) were found in about
10 % of either group. Two patients in each treatment group
≥1 major renal BVAS/WG item, which includes new or worsening events of the following two 
symptoms: 
Red blood cell casts;
A rise in creatinine >30% or a fall in creatinine clearance >25%;
and/or
Biopsy proven pauci-immune glomerulonephritis.
Box 1: Definition of major renal disease in the RAVE study [11]
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died. No additional safety issues were detected in patients
followed for C18 months [38], including no difference in
new malignancies between the groups (6 and 2 cases in the
rituximab and cyclophosphamide groups, respectively;
further details are available in Stone et al. [11]).
RITUXVAS was a multicenter open-label study that
recruited patients with newly diagnosed AAV and renal
involvement (severe GPA/MPA) [12]. Patients enrolled in
RITUXVAS were older (median age 68 years) than the
patients in the RAVE cohort (mean age 51–54 years) and
had worse renal function at baseline (median GFR
12–20 ml/min in RITUXVAS and mean GFR 54–69 ml/
min in RAVE). Study participants were randomized to
treatment with rituximab (375 mg/m2 once weekly for
4 weeks) plus two IV cyclophosphamide pulses, or IV
cyclophosphamide for 3–6 months (control group). For
remission-maintenance, the control group received oral
azathioprine for up to 12 months. This trial included
patients who had severe renal disease, with 9/44 patients
requiring dialysis at trial entry. All patients received the
same glucocorticoid regimen of IV methylprednisolone
1,000 mg, followed by oral prednisolone 1 mg/kg/day,
tapered to 5 mg/day by 6 months. Rates of sustained
remission (over 12 months) were high in both treatment
groups, although they did not differ significantly: ritux-
imab/cyclophosphamide 76 % (25/33) and cyclophospha-
mide 82 % (9/11) (P = 0.68). Mortality in this older,
renal-impaired group was high (18 %) in both treatment
groups, although the incidence of serious AEs and infec-
tions was similar in the two treatment groups.
Rituximab for remission-induction in refractory GPA/
MPA
EUVAS defines refractory disease as progressive disease
unresponsive to cyclophosphamide and corticosteroids
[13]. Among GPA/MPA patients receiving standard ther-
apy of cyclophosphamide and glucocorticoids, up to 5 %
are refractory to treatment (see Table 1) [39]. The first use
of rituximab to treat refractory vasculitis was described in
2001 [40]. Other groups have since shown that rituximab is
effective at inducing remission in GPA/MPA patients with
refractory disease [41–43]. In one multicenter series
involving 65 patients with refractory disease, complete
remission was achieved in 75 % of patients treated with
rituximab [44].
Glucocorticoid taper
As high-dose glucocorticoid treatment is associated with
considerable toxicity, implementing measures to reduce
glucocorticoid exposure without increasing the risk of
relapse is critical. Current remission-induction regimens
include high-dose glucocorticoids, which are then tapered
when remission is achieved [13]. The relationship between
glucocorticoid dose and its immunosuppressive and anti-
inflammatory actions is complex [45].
When combined with cytotoxic medications, high-dose
glucocorticoids may increase treatment-related toxicity.
Infections in GPA/MPA are most common in the first
2 months of treatment when glucocorticoid doses are
highest. Although this relationship is confounded by dis-
ease activity and co-treatment with cytotoxic therapy, it is
important to note that infection rates fall in parallel with
decreasing glucocorticoid dose despite the maintenance of
cytotoxic agents. Glucocorticoid dose-dependent increases
in infections have been observed in RA [46]. Furthermore,
high cumulative doses of glucocorticoids are associated
with other comorbidities, including osteoporosis, cardio-
vascular disease, and gastrointestinal bleeding [47].
Despite the evidence for an association between higher
glucocorticoid doses and AEs, there is a paucity of evi-
dence to guide the optimal glucocorticoid dosing in GPA/
MPA.
Results from RAVE and RITUXVAS indicate that glu-
cocorticoid tapering can be achieved during remission-
induction with either rituximab or cyclophosphamide. In
RAVE, patients received 1–3 pulses of IV methylpredniso-
lone (1,000 mg each), followed by oral prednisone (1 mg/
kg/day) with dose tapering, such that by 5 months all patients
in remission without disease flare had discontinued gluco-
corticoids completely [11]. The glucocorticoid taper occur-
red later in RITUXVAS: the prednisolone dose was 5 mg/
day at 6 months [12]. By 12 months, the median weight-
adjusted doses of prednisolone were still approximately
5 mg daily (0.071 and 0.082 mg/kg/day) in the rituximab
and control groups, respectively. Another uncontrolled study
in patients with renal AAV, involving induction therapy with
low-dose cyclophosphamide plus rituximab followed by
azathioprine maintenance, employed a low-dose glucocor-
ticoid regimen with withdrawal at 3 months [48]. This
strategy proved effective, with a relapse rate of only 13 %
over 18 months and an acceptable safety profile. The PEX-
IVAS trial is designed to determine the non-inferiority of a
reduced-dose glucocorticoid regimen compared with stan-
dard-dose glucocorticoids in reducing death and ESRD.
If the decision is made to use a remission-maintenance
regimen in AAV, low-dose glucocorticoids are often used
in combination with azathioprine or methotrexate. The
optimal dose and duration of glucocorticoid therapy in
relapse prevention have not been established. The efficacy
of long-term, low-dose glucocorticoids to prevent relapses
is controversial and must be balanced with the risk of AEs
due to toxicity from high cumulative doses of glucocorti-
coids. A systematic review and meta-analysis of 13 studies
(n = 983) concluded that longer courses of glucocorticoids
J Nephrol (2015) 28:17–27 21
123
were associated with fewer relapses and that low-dose
glucocorticoids for [12 months would be anticipated to
provide benefits for patients [18]. In contrast, a cohort
study that evaluated the effect of glucocorticoid therapy on
patient outcomes and AEs reported that therapy beyond
6 months was associated with a significantly greater risk of
infections but no significant reduction in the rate of relapse
[49].
Rituximab as maintenance immunosuppressive therapy
in GPA/MPA
GPA and MPA are relapsing diseases, with approximately
50 % of patients following a chronic relapsing pattern,
despite standard immunosuppression. Studies have shown
that relapse may be more common in anti-proteinase
3-positive patients [50, 51]. The use of rituximab as
maintenance therapy to prevent relapses in AAV has been
evaluated in two open-label studies. In one study, 2-year
fixed-interval re-treatment with rituximab was shown to
lower relapse rate and maintain remission for a prolonged
period compared with rituximab treatment at the time of
flare [52]. Administration of rituximab preemptively on the
basis of B-cell repletion has also been shown to be effec-
tive in preventing relapses [53]. Other open-label studies
have confirmed the effectiveness of rituximab as a main-
tenance immunosuppressive agent [54, 55]. A recent ret-
rospective analysis of 172 patients with ANCA vasculitis
treated with scheduled rituximab dosing every 4 months
demonstrated achievement of continuous B-cell depletion
and long-term disease control [56]. Controlled trials testing
the effectiveness of rituximab as maintenance therapy are
under way. Initial results from a prospective, randomized,
controlled trial (MAINRITSAN) of patients with newly
diagnosed (n = 91) or relapsing (n = 23) AAV who had
achieved remission with standard therapy showed that rates
of major relapse during maintenance therapy were lower
among patients who received rituximab 500 mg every
6 months than among those receiving azathioprine (5.2
versus 25.4 %) [57]. Another EUVAS randomized con-
trolled trial (RITAZAREM) will investigate maintenance
therapy with rituximab in patients with relapsing GPA/
MPA. Patients in remission at 4 months following ritux-
imab (4 9 375 mg/m2) will receive maintenance therapy
with fixed-interval, repeat dosing with rituximab (1,000 mg
every 4 months for 5 doses) or azathioprine [58]. Patients
will be followed after cessation of therapy to test the
hypothesis that repeat-dose rituximab during remission
induces lasting remission through depletion of auto-reac-
tive memory B cells.
An emerging observation with repeated rituximab
exposure has been the development of hypogammaglobu-
linemia, which may increase in frequency in patients who
have previously been exposed to cyclophosphamide before
rituximab treatment [59]. In RAVE, a substantial propor-
tion of GPA/MPA patients had low immunoglobulin levels
at baseline, and low immunoglobulin levels were not
associated with an increased risk of infection [60]. Simi-
larly, a single-center study reported that 21 % of patients
had IgG levels below the lower limit of normal before
rituximab treatment, with a trend toward lower levels after
rituximab treatment over 2 years [52]. As reported for the
RAVE cohort, there was no clear association between
hypogammaglobulinemia and infections.
For patients who have previously relapsed on mainte-
nance therapies, such as azathioprine or MMF, continuing
these agents after rituximab appears to have little benefit
[44]. Whether they reduce the risk of relapse after ritux-
imab in treatment-naı¨ve patients is not known.
In summary, available data indicate that once remission
has been achieved, rituximab therapy using a fixed-interval
re-treatment schedule is a potential alternative to azathio-
prine for remission-maintenance. The clinical importance
of hypogammaglobulinemia with scheduled repeat doses of
rituximab will be prospectively studied in ongoing and
planned maintenance trials.
Rituximab in managing GPA/MPA patients with severe
renal disease
Concomitant use of cyclophosphamide
The time to remission (defined as absence of clinical disease
activity and a BVAS score of zero) after a rituximab course
has been around 2 months whether or not concomitant ther-
apy with cyclophosphamide was used. The RITUXVAS trial
enrolled older patients with more severe renal disease, with a
median e-GFR of 20 ml/min, and included dialysis-depen-
dent patients. Rituximab-treated patients received two doses
of IV cyclophosphamide 15 mg/kg with the first course of
rituximab [12]. Remission occurred in 91 % of patients
treated with rituximab, and at 12 months 76 % had sustained
remission and a median e-GFR of 39 ml/min. However, in
this older group with worse renal function at baseline, the
mortality was 18 % in each group. A single-center prospec-
tive study of 23 ANCA-associated renal vasculitis patients
with a median e-GFR of 24 ml/min also used a lower dose of
cyclophosphamide (10 mg/kg) with the initial course of rit-
uximab [48]. Twenty-two of the 23 patients achieved
remission and the median e-GFR was 42 ml/min by
6 months.
Plasma exchange
Plasma exchange is recommended as an adjunct to remis-
sion-induction therapy for selected patients with rapidly
22 J Nephrol (2015) 28:17–27
123
progressive severe renal disease in order to improve renal
survival [25]. It is also recommended for certain patients
with severe pulmonary disease and pulmonary hemorrhage.
An open-label, randomized, controlled study is under way
(PEXIVAS; NCT01697267), which aims to clearly deter-
mine both the role of plasma exchange in severe AAV and
whether glucocorticoid dosing can be safely reduced.
PEXIVAS will randomize patients with severe AAV to one
of four study groups: plasma exchange ? standard-dose
glucocorticoids; plasma exchange ? reduced-dose gluco-
corticoids; no plasma exchange ? standard-dose gluco-
corticoids; or no plasma exchange ? reduced-dose
glucocorticoids. Although induction therapy will in most
cases involve standard cyclophosphamide/high-dose glu-
cocorticoids, rituximab is a permitted alternative for suit-
able patients. In such cases, rituximab should be dosed
after the plasma exchange because of the potential for
rituximab to be removed by plasma exchange.
Unique populations
Transplantation
In patients with ESRD, kidney transplantation improves
survival compared with maintenance dialysis. Patients with
renal AAV who receive transplantation appear to have
reduced rates of vasculitis relapse compared with those
who remain on dialysis [61]. However, relapse remains a
significant clinical issue in transplant patients and selection
of the optimal treatment for maintaining remission is
clearly critical. Reintroduction of a cyclophosphamide/
high-dose glucocorticoid regimen has shown some success,
albeit in a limited number of patients [62]. The use of
rituximab in GPA/MPA patients post-transplantation has
not been evaluated extensively, although a number of case
reports suggest that rituximab is an effective alternative to
standard induction therapy in this situation [63, 64].
Pregnancy
There is no evidence of a teratogenic risk with rituximab.
However, given the lack of adequate data on safety on fetal
exposure, rituximab is categorized as Category C drug, and
effective contraception prior to the first infusion is rec-
ommended. In an assessment of the global safety database
for rituximab in women who became pregnant, some
complications and neonatal abnormalities were reported
[65]. However, these may have been confounded by con-
comitant use of potentially teratogenic medications and
severe underlying disease. Use of rituximab later in preg-
nancy is associated with B-cell depletion and low IgM
levels in the newborn [66]. In a recent report of 157 women
with vasculitis including 22 under the age of 40, 6 patients
undergoing treatment with rituximab became pregnant
[56]. There were eight pregnancies in total. One miscar-
riage occurred at 15 weeks, and the rest of the pregnancies
were uneventful. Maternal B cells were depleted at the time
of delivery, while B-cell levels were normal in the fetal
cord blood. In an individual case, the potential risks of
rituximab in pregnancy must be balanced against the ben-
efits of improved disease control and avoidance of other
potentially toxic agents. Rituximab is classified by the FDA
as a Category C drug with respect to pregnancy.
Rituximab dosing
The initial experience with rituximab in severe and
refractory GPA/MPA used a regimen of 375 mg/m2 once
weekly for 4 weeks (4 9 375 mg/m2), and this dose and
schedule was selected for the prospective RAVE and
RITUXVAS trials and is the approved dose in the FDA
label. This regimen has been used in most published studies
to date, and results in a higher total dose than the standard
regimen used in RA (two 1,000-mg infusions separated by
2 weeks). There have not been any dose-ranging studies in
vasculitis to determine the optimal protocol, although one
retrospective series of 65 patients reported that the
4 9 375 mg/m2 and 2 9 1,000-mg regimens induced
similar rates of remission (81 and 75 %, respectively) [44].
Another recent single- center experience with a protoco-
lized treatment of ANCA vasculitis with a single dose of
rituximab 375 mg/m2 demonstrated that the duration of
B-cell depletion was similar to those reported in observa-
tional studies and an excellent clinical response with a
3-month probability of complete remission of 80 % and
significant cost savings [67].
Rituximab side effects
As of 2013 more than 220,000 patients have received rit-
uximab for the treatment of RA (Roche/Genentech, data on
file). Long-term follow-up data for patients treated with
rituximab in RA indicate that it also has a good safety
profile [68]. Nonetheless, rituximab use is associated with
specific side effects, some of which can be fatal (these are
fully reviewed in the product label [69]). Infusion-related
reactions, most commonly on the initial infusion, can
occur, and symptoms of serum-like sickness can develop
later. Rituximab is a potent immunosuppressive agent and,
as such, increases the risk of infections. However, rates of
serious infections in rituximab-treated RA patients were
similar to those reported in the general RA population, and
there was no increased risk for opportunistic infections
[68]. In the RAVE trial, 10 % of patients suffered serious
infections (sepsis or pneumonia). Although there have been
reports of use of rituximab for remission-induction in the
J Nephrol (2015) 28:17–27 23
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setting of severe infection, this use is not recommended,
and the risks and benefits of such therapy must be weighed
carefully [70]. Late-onset neutropenia has been observed
with rituximab, but without increasing the risk of serious
infections [56, 71]. Hypogammaglobulinemia is common
during treatment with rituximab [60]; however, it remains
to be fully determined if rituximab-induced hypogamma-
globulinemia is associated with an increased risk of
infection. Progressive multifocal leukoencephalopathy
(PML) has occurred in association with rituximab in other
indications [72], although it is very rare [\1 case in 10,000
patient exposures in RA patients treated with rituximab
(Roche/Genentech, data on file)]. Four cases of PML have
been reported in patients with GPA in the absence of
exposure to rituximab [72]. As of January 2013, there has
been one confirmed case of PML in a 70-year-old breast
cancer patient with GPA treated with rituximab and
cyclophosphamide (Roche/Genentech, data on file). Rit-
uximab has been reported to reactivate hepatitis B infec-
tions at times with severe consequences, and testing
patients for HBsAg and anti HB core antibody is recom-
mended. Although data in RA cannot be generalized to
GPA/MPA, the long-term experience in rheumatology
suggests that rituximab is not associated with an increased
malignancy risk.
When is rituximab the first line of therapy
in ANCA-associated vasculitis?
Based on available data, rituximab is the first line of
therapy for induction of remission in patients who have
severe AAV refractory to use of cyclophosphamide. Rit-
uximab is preferred for induction of remission in severe
AAV in young patients who wish to preserve fertility.
Rituximab is superior to cyclophosphamide in patients with
relapsing disease, especially those who are PR3 ANCA
positive. However, the utility of rituximab alone in
severely ill patients, such as those with renal involvement
requiring dialysis at presentation and alveolar hemorrhage
requiring mechanical ventilation, needs further study.
Conclusions
The combination of cyclophosphamide and high-dose
glucocorticoids has remained the standard of care approach
for remission-induction for the majority of patients with
GPA or MPA over four decades. The high rate of remission
achieved using this regimen means that it will remain an
important therapeutic option. However, some patients fail
to achieve remission with cyclophosphamide/glucocorti-
coid therapy, others suffer relapses during treatment, and
there are well-recognized long-term toxicities associated
with this regimen. Cyclophosphamide is not FDA approved
for the treatment of ANCA-associated vasculitis. The
availability of rituximab, which is FDA approved for this
indication, now offers an alternative treatment option for
the induction of remission in severe GPA/MPA. Rituximab
may be considered a first choice therapy for patients with
relapsing disease based on the RAVE data, and may be the
preferred therapy for remission-induction for some young
patients who wish to preserve fertility. The unanswered
issues in the role of rituximab as an induction immuno-
suppressive agent include the use of concomitant cyclo-
phosphamide and adjuvant plasma exchange for patients
with life-threatening disease manifestations, and approa-
ches to limit glucocorticoid exposure given the high inci-
dence of AEs. The ongoing MAINRITSAN and
RITAZAREM studies should provide a clearer picture of
rituximab’s safety and efficacy as maintenance therapy in
the management of GPA/MPA.
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